Who is sponsoring NCT01138111?

NCT01138111 is sponsored by Life Molecular Imaging SA.

What condition does NCT01138111 study?

NCT01138111 studies Alzheimer Disease, Amyloid Beta-Protein.

What drugs are being tested in NCT01138111?

Interventions: Florbetaben (BAY94-9172).

What is the status of NCT01138111?

NCT01138111 is currently COMPLETED.

Last reviewed 2014-05-22 · How we verify

ß-amyloid Imaging With BAY94-9172 Positron Emission Tomography for Early Detection of Alzheimer's Disease in Patients With Mild Cognitive Impairment

NCT01138111 Phase 1 COMPLETED Results posted

The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from those with MCI not progressing to AD.

Details

Lead sponsor	Life Molecular Imaging SA
Phase	Phase 1
Status	COMPLETED
Enrolment	45
Start date	2008-06
Completion	2011-12

Conditions

Alzheimer Disease
Amyloid Beta-Protein

Interventions

Florbetaben (BAY94-9172)

Primary outcomes

Quantitative Assessment of Neocortical SUVRs (Mean Standard Uptake Value Ratios) as a Measure of Florbetaben Uptake — 1 scanning period post injection to be evaluated at baseline, 12 months and 24 months
Mean SUVRs were calculated for subjects who did and did not progress to Alzheimer's Disease (AD) during the study for each PET scan time point (baseline, 12 and 24 months)

Countries

Australia